Benefits of a Juvenile Arthritis Support Program (JASP-1) for children recently diagnosed with Juvenile Idiopathic Arthritis and their parents.
JIA
Patient outcome assessment
Patient satisfaction
Support program
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
15 Aug 2024
15 Aug 2024
Historique:
received:
17
06
2024
accepted:
01
08
2024
medline:
15
8
2024
pubmed:
15
8
2024
entrez:
14
8
2024
Statut:
epublish
Résumé
Medical treatment for children with Juvenile Idiopathic Arthritis (JIA) has improved radically since the development of biological disease-modifying antirheumatic drugs. However, children suffer from pain and anxiety, and parents often experience loneliness and lack of support. Some parents reported that information provided at the time their child was diagnosed could be difficult to assimilate. Therefore, the aim of this study was to develop a Juvenile Arthritis Support Program (JASP-1) for children recently diagnosed with JIA and their parents. Moreover, the aim was to explore patients´ and parents´ experiences with JASP-1 and its potential impact on patients´ physical health. JASP-1 included seven patient- and family-centered clinical visit from time of diagnose and one year ahead. Data were collected from a study-specific questionnaire answered by children and their parents after participation in JASP-1 and from the pediatric rheumatology register. The study-specific questionnaire explored participants´ experience with the care they received during their first year with JIA. Registry and questionnaire data from the intervention (JASP-1) group was compared to a control group. The analysis revealed that children and parents who completed JASP-1 were more satisfied with the care they had received during their first year with JIA than the control group. The results also showed that children who completed JASP-1 were assessed as having better overall health after 12 months, than children in the control group (JASP-1 = mean 4.33, 95% Confidence Interval (CI) 4.17 - 4.46), (Control = mean 3.68, 95% CI 3.29 - 4.06), (p = 0.002). Moreover, children in the JASP-1 group had less disease impact on daily life (JASP-1 = mean 0.15, 95% CI 0.07 - 0.24) (Control = mean 0.40, 95% CI 0.13 - 0.67), (p = 0.017) and less active joints than the control group (JASP-1 = mean 0.62, 95% CI 0.35 - 1.58), (Control = mean 0.87, 95% CI 0.18 - 1.56), (p = 0.054). A support program like JASP-1 could be an effective way of not only supporting children newly diagnosed with JIA and their parents psychologically but may also increase children's overall physical health and improve quality of care within pediatric rheumatology. Retrospectively registered in ClinicalTrials.gov, the 13th of February with ID NCT06284616.
Sections du résumé
BACKGROUND
BACKGROUND
Medical treatment for children with Juvenile Idiopathic Arthritis (JIA) has improved radically since the development of biological disease-modifying antirheumatic drugs. However, children suffer from pain and anxiety, and parents often experience loneliness and lack of support. Some parents reported that information provided at the time their child was diagnosed could be difficult to assimilate. Therefore, the aim of this study was to develop a Juvenile Arthritis Support Program (JASP-1) for children recently diagnosed with JIA and their parents. Moreover, the aim was to explore patients´ and parents´ experiences with JASP-1 and its potential impact on patients´ physical health.
METHODS
METHODS
JASP-1 included seven patient- and family-centered clinical visit from time of diagnose and one year ahead. Data were collected from a study-specific questionnaire answered by children and their parents after participation in JASP-1 and from the pediatric rheumatology register. The study-specific questionnaire explored participants´ experience with the care they received during their first year with JIA. Registry and questionnaire data from the intervention (JASP-1) group was compared to a control group.
RESULTS
RESULTS
The analysis revealed that children and parents who completed JASP-1 were more satisfied with the care they had received during their first year with JIA than the control group. The results also showed that children who completed JASP-1 were assessed as having better overall health after 12 months, than children in the control group (JASP-1 = mean 4.33, 95% Confidence Interval (CI) 4.17 - 4.46), (Control = mean 3.68, 95% CI 3.29 - 4.06), (p = 0.002). Moreover, children in the JASP-1 group had less disease impact on daily life (JASP-1 = mean 0.15, 95% CI 0.07 - 0.24) (Control = mean 0.40, 95% CI 0.13 - 0.67), (p = 0.017) and less active joints than the control group (JASP-1 = mean 0.62, 95% CI 0.35 - 1.58), (Control = mean 0.87, 95% CI 0.18 - 1.56), (p = 0.054).
CONCLUSION
CONCLUSIONS
A support program like JASP-1 could be an effective way of not only supporting children newly diagnosed with JIA and their parents psychologically but may also increase children's overall physical health and improve quality of care within pediatric rheumatology.
TRIAL REGISTRATION
BACKGROUND
Retrospectively registered in ClinicalTrials.gov, the 13th of February with ID NCT06284616.
Identifiants
pubmed: 39143588
doi: 10.1186/s41927-024-00404-8
pii: 10.1186/s41927-024-00404-8
doi:
Banques de données
ClinicalTrials.gov
['NCT06284616']
Types de publication
Journal Article
Langues
eng
Pagination
35Informations de copyright
© 2024. The Author(s).
Références
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.
pubmed: 14760812
Berntson L, Andersson Gare B, Fasth A, Herlin T, Kristinsson J, Lahdenne P, et al. Incidence of juvenile idiopathic arthritis in the nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol. 2003;30(10):2275–82.
pubmed: 14528529
Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol. 2015;11(5):290–300.
doi: 10.1038/nrrheum.2014.212
pubmed: 25561365
Consolaro A, Ravelli A. Paediatric rheumatology: juvenile idiopathic arthritis–are biologic agents effective for pain? Nat Rev Rheumatol. 2013;9(8):447.
doi: 10.1038/nrrheum.2013.108
pubmed: 23820859
Haverman L, Grootenhuis MA, van den Berg JM, van Veenendaal M, Dolman KM, Swart JF, et al. Predictors of health-related quality of life in children and adolescents with juvenile idiopathic arthritis: results from a web-based survey. Arthritis Care Res (Hoboken). 2012;64(5):694–703.
doi: 10.1002/acr.21609
pubmed: 22238240
Sawyer MG, Whitham JN, Roberton DM, Taplin JE, Varni JW, Baghurst PA. The relationship between health-related quality of life, pain and coping strategies in juvenile idiopathic arthritis. Rheumatology (Oxford). 2004;43(3):325–30.
doi: 10.1093/rheumatology/keh030
pubmed: 14566031
Fair DC, Rodriguez M, Knight AM, Rubinstein TB. Depression and anxiety in patients with juvenile idiopathic arthritis: current insights and impact on quality of life, a systematic review. Open Access Rheumatol. 2019;11:237–52.
doi: 10.2147/OARRR.S174408
pubmed: 31807093
pmcid: 6830373
Yuwen W, Lewis FM, Walker AJ, Ward TM. Struggling in the Dark to help my child: parents’ experience in caring for a young child with juvenile idiopathic arthritis. J Pediatr Nurs. 2017;37:e23–9.
doi: 10.1016/j.pedn.2017.07.007
pubmed: 28778610
pmcid: 5681389
Heath-Watson S, Sule S. Living with juvenile idiopathic arthritis: parent and physician perspectives. Rheumatol Ther. 2018;5(1):1–4.
doi: 10.1007/s40744-018-0098-2
pubmed: 29480358
pmcid: 5935629
Sunthornsup W, Vilaiyuk S, Soponkanaporn S. Effect of educational brochure compared with video on disease-related knowledge in patients with juvenile idiopathic arthritis: a randomized controlled trial. Front Pediatr. 2022;10:1048949.
doi: 10.3389/fped.2022.1048949
pubmed: 36568417
pmcid: 9780585
André M, Hagelberg S, Stenström CH. Education in the management of juvenile chronic arthritis. Changes in self-reported competencies among adolescents and parents of young children. Scand J Rheumatol. 2001;30(6):323–7.
pubmed: 11846049
Gilljam B-M, Arvidsson S, Nygren JM, Svedberg P. Promoting participation in healthcare situations for children with JIA: a grounded theory study. Int J Qualitative Stud Health well-being. 2016;11(1):30518–10.
doi: 10.3402/qhw.v11.30518
Institute for patient- and family-centered care. Patient- and Family-centered care 2022, Nov 15 [ https://www.ipfcc.org/about/pfcc.html
The American Academy of Pediatrics. Patient- and family-centered care and the pediatrician’s role. Pediatrics. 2012;129(2):394–404.
doi: 10.1542/peds.2011-3084
Swedish Pediatric Rheumatology Quality Register [Internet]. 2021 [cited 2023]. https://barnreumaregistret.se
Andersson Gäre B, Fasth A, Andersson J, Berglund G, Ekström H, Eriksson M, et al. Incidence and prevalence of juvenile chronic arthritis: a population survey. Ann Rheum Dis. 1987;46(4):277–81.
doi: 10.1136/ard.46.4.277
pubmed: 3592782
pmcid: 1002119
Ramelet AS, Fonjallaz B, Rio L, Zoni S, Ballabeni P, Rapin J, et al. Impact of a nurse led telephone intervention on satisfaction and health outcomes of children with inflammatory rheumatic diseases and their families: a crossover randomized clinical trial. BMC Pediatr. 2017;17(1):168.
doi: 10.1186/s12887-017-0926-5
pubmed: 28716081
pmcid: 5513092
WHO WHO. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference. New York, 19–22. June, 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948: WHO; 1946 [.
Leonardi F. The definition of Health: towards New perspectives. Int J Health serv: Plann Adm Evaluation. 2018;48(4):735–48.
doi: 10.1177/0020731418782653
van Dijkhuizen EHP, Egert T, Egert Y, Costello W, Schoemaker C, Fernhout M, et al. Patient’s experiences with the care for juvenile idiopathic arthritis across Europe. Pediatr Rheumatol Online J. 2018;16(1):10.
doi: 10.1186/s12969-018-0226-0
pubmed: 29422094
pmcid: 5806356